ライフサイエンスコーパス: cardiovascular outcome

1 the association of moderate alcohol use with cardiovascular outcomes.

2 excretion and risk of blood pressure-related cardiovascular outcomes.

3 4-1.71, P=0.12) were associated with adverse cardiovascular outcomes.

4 ht improve survival and both respiratory and cardiovascular outcomes.

5 Frailty is an independent risk factor for cardiovascular outcomes.

6 terone-replacement therapy and major adverse cardiovascular outcomes.

7 e of calcium, with or without vitamin D, and cardiovascular outcomes.

8 , and shorter LTL is associated with adverse cardiovascular outcomes.

9 tes of postdischarge readmission and adverse cardiovascular outcomes.

10 lative to diabetes support and education, on cardiovascular outcomes.

11 en shown to improve endothelial function and cardiovascular outcomes.

12 tion of stable chest pain with follow-up for cardiovascular outcomes.

13 l venules have been associated with negative cardiovascular outcomes.

14 ve follow-up data regarding post-MRI adverse cardiovascular outcomes.

15 zetimibe versus simvastatin alone in 6-month cardiovascular outcomes.

16 isit-to-visit variability in LDL-C levels on cardiovascular outcomes.

17 Is) and dual antiplatelet therapy (DAPT) for cardiovascular outcomes.

18 e-lowering drugs or strategies that assessed cardiovascular outcomes.

19 sociation between CFR, angiographic CAD, and cardiovascular outcomes.

20 lesion site (CLS) thrombus is a predictor of cardiovascular outcomes.

21 reduction in proteinuria improves renal and cardiovascular outcomes.

22 sociated with AF and associations of AF with cardiovascular outcomes.

23 ering of LDL cholesterol levels and improved cardiovascular outcomes.

24 VRS may therefore have beneficial effects on cardiovascular outcomes.

25 owering drugs or strategies adversely affect cardiovascular outcomes.

26 ut consumption is associated with beneficial cardiovascular outcomes.

27 We also assessed secondary safety and cardiovascular outcomes.

28 se of aleglitazar did not reduce the risk of cardiovascular outcomes.

29 of left atrial size and function to predict cardiovascular outcomes.

30 t of coronary artery calcification and other cardiovascular outcomes.

31 CTs) and meta-analyses of RCTs that examined cardiovascular outcomes.

32 unction and has been associated with adverse cardiovascular outcomes.

33 specified component of the primary composite cardiovascular outcomes.

34 Cox regression to estimate hazard ratios for cardiovascular outcomes.

35 re characterized and correlated with adverse cardiovascular outcomes.

36 als have evaluated drug therapy on HDL-C and cardiovascular outcomes.

37 lve replacement and is associated with worse cardiovascular outcomes.

38 l manipulation of HDL-C has not improved the cardiovascular outcomes.

39 ents failed to demonstrate an improvement in cardiovascular outcomes.

40 embrane permeability and dialysate purity on cardiovascular outcomes.

41 renal stress hormone associated with adverse cardiovascular outcomes.

42 ors have shown neutral or adverse effects on cardiovascular outcomes.

43 a, adding ASV to OMT did not improve 6-month cardiovascular outcomes.

44 race-stratified associations between BP and cardiovascular outcomes.

45 h-sensitivity cardiac troponin I (hsTnI) and cardiovascular outcomes.

46 d is associated with atrial fibrillation and cardiovascular outcomes.

47 ifestyle, and other environmental factors on cardiovascular outcomes.

48 progenitor cells and their impact on adverse cardiovascular outcomes.

49 mates of sodium and potassium excretion with cardiovascular outcomes.

50 all aspects of these disparities to improve cardiovascular outcomes.

51 , and shorter LTL is associated with adverse cardiovascular outcomes.

52 ubsequent systemic inflammation, and adverse cardiovascular outcomes.

53 3.1) for DDKF and 6.3 (95% CI, 2.7-15.0) for cardiovascular outcomes.

54 ta linking fertility therapy with subsequent cardiovascular outcomes.

55 ns: (1) does BP lowering reduce all types of cardiovascular outcome?

56 been shown capable of reducing all types of cardiovascular outcome?

57 Of 3 secondary prevention studies reporting cardiovascular outcomes, 1 found a lower risk for recurr

58 of hypertension treatment affects patients' cardiovascular outcomes according to their body size.

59 ACE use in blacks was associated with poorer cardiovascular outcomes (ACE vs. NoACE: 8.69% vs. 7.74%;

60 dels were used to estimate hazard ratios for cardiovascular outcomes adjusted for known predictors, i

61 m Hg on treatment, the risk of the composite cardiovascular outcome (adjusted hazard ratio [HR] 1.14,

62 pothermia rapidly is critical to improve the cardiovascular outcome after cardiac arrest with underly

63 d is not a useful strategy to reduce adverse cardiovascular outcomes after ACS.

64 ers are associated with an increased risk of cardiovascular outcomes after AMI, but little is known a

65 pective cohort study was conducted to assess cardiovascular outcomes after an arterial switch operati

66 s of recurrent lower GI bleeding and serious cardiovascular outcomes after aspirin-associated lower G

67 h long-term risks for mortality and nonfatal cardiovascular outcomes after early catheterization that

68 ed the effect of active IBD on major adverse cardiovascular outcomes after myocardial infarction (MI)

69 eral arterial disease (PAD) experience worse cardiovascular outcomes after percutaneous coronary inte

70 e risk of long-term, all-cause mortality and cardiovascular outcomes after sepsis.

71 to assess the benefits of LDL-C lowering on cardiovascular outcomes among individuals with primary e

72 lar risk factors at target and major adverse cardiovascular outcomes among patients with T1DM.

73 f the adjusted excess risk varies by type of cardiovascular outcome and across populations by age and

74 here are few data on the association between cardiovascular outcome and GLS in the community.

75 ociations between beta-blocker treatment and cardiovascular outcome and mortality in AF patients with

76 o, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when

77 an increased risk of a composite of nonfatal cardiovascular outcomes and all-cause mortality.

78 y sought to describe the acute and long-term cardiovascular outcomes and assess the predictors of rec

79 ects of intensive SBP lowering on kidney and cardiovascular outcomes and contrast its apparent benefi

80 vement in the net reclassification index for cardiovascular outcomes and death compared with prediabe

81 PM2.5) are associated with increased risk of cardiovascular outcomes and death, but their association

82 he prognostic role of the CPC/EPC measure on cardiovascular outcomes and death.

83 perties represents a risk factor for adverse cardiovascular outcomes and death.

84 t net protection of SGLT2 inhibitors against cardiovascular outcomes and death.

85 of menopause as exposures as well as risk of cardiovascular outcomes and intermediate CVD end points

86 To evaluate national trends in perioperative cardiovascular outcomes and mortality after major noncar

87 g and the effects of testosterone therapy on cardiovascular outcomes and mortality are unknown.

88 Endogenous sex hormones have been related to cardiovascular outcomes and mortality.

89 marker for a therapeutic regimen's impact on cardiovascular outcomes and patient survival.

90 rameter, is associated with multiple adverse cardiovascular outcomes and provides prognostic utility

91 sociated with an increased risk of death and cardiovascular outcomes and should merit further attenti

92 subclinical hypothyroidism adversely affects cardiovascular outcomes and thus merits case-finding.

93 ded to clarify the role of menarcheal age on cardiovascular outcomes and to investigate the potential

94 , the EMPA-REG OUTCOME trial (Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabete

95 The Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabete

96 In a landmark trial called Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabete

97 ke-singly and as a composite endpoint, major cardiovascular outcome-and end-stage renal disease [ESRD

98 ve and functional decline as well as adverse cardiovascular outcomes; and (4) hypertension may be ben

99 ciated with a significant reduction in major cardiovascular outcomes: ARB (odds ratio [OR] 1.02; 95%

100 y be associated with wildfire smoke, whether cardiovascular outcomes are associated with wildfire smo

101 whether long-term adverse neurocognitive and cardiovascular outcomes are attributable to mild OSA in

102 Dalcetrapib effects on cardiovascular outcomes are determined by adenylate cycl

103 lycemic control, but their associations with cardiovascular outcomes are uncharacterized.

104 e the individual components of the composite cardiovascular outcome, as well as incident atrial fibri

105 Previous studies have not addressed cardiovascular outcomes associated with MH and white-coa

106 hypertensive target organ damage and adverse cardiovascular outcomes associated with WCH (high clinic

107 ssified according to CI-AKI development, and cardiovascular outcomes at 30 days and 1 year were compa

108 Other cardiovascular outcomes attributed to AF, including stro

109 significantly improved the discrimination of cardiovascular outcomes beyond traditional risk factors

110 on interventions have an uncertain effect on cardiovascular outcomes, but CBT combined with antidepre

111 /= 2.5 mum) has been associated with adverse cardiovascular outcomes, but it is unclear whether speci

112 tudy Outcomes Model 2 (for microvascular and cardiovascular outcomes, C-statistics 0.54-0.62, slopes

113 g (requiring hospitalization) or a composite cardiovascular outcome (cardiovascular death, nonfatal r

114 Composite cardiovascular outcomes (cardiovascular deaths, nonfatal

115 with 3) exposure to fertility therapy and 4) cardiovascular outcomes clearly reported; 5) presence of

116 our CETP inhibitors have advanced to phase 3 cardiovascular outcome clinical trials, and two have bee

117 Five cardiovascular outcomes compared between patients with a

118 or cardiovascular events had higher rates of cardiovascular outcomes compared with the primary preven

119 is associated with a higher risk of adverse cardiovascular outcomes (compared with patients with no

120 Evolocumab significantly reduced cardiovascular outcomes consistently in patients with an

121 ation between arterial stiffness and various cardiovascular outcomes (coronary heart disease, stroke)

122 ssociations between WCH and MH with incident cardiovascular outcomes (coronary heart disease, stroke,

123 and low CD34+ levels (<Q1) predicted adverse cardiovascular outcomes (death, myocardial infarction, c

124 through 2014, mortality and the incidence of cardiovascular outcomes declined substantially among per

125 or reducing these adverse neurocognitive and cardiovascular outcomes, delineate the key research gaps

126 2C19 loss-of-function (LoF) allele and major cardiovascular outcomes differed significantly (P<0.001)

127 etween CYP2C19 LoF allele carriage and major cardiovascular outcomes differs based on the ethnic popu

128 p between achieved LDL cholesterol and major cardiovascular outcomes down to LDL-cholesterol concentr

129 ailure was associated with a lower composite cardiovascular outcome driven by lower risk of recurrent

130 ment is a recognized risk factor for adverse cardiovascular outcomes, emerging evidence supports the

131 increases risks for adverse respiratory and cardiovascular outcomes, especially among certain suscep

132 igh uric acid is causally related to adverse cardiovascular outcomes, especially sudden cardiac death

133 eople with type 2 diabetes have investigated cardiovascular outcomes, even though most patients die f

134 in the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Me

135 The EMPA-REG OUTCOME trial ([Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Me

136 Of the 5 cardiovascular outcomes examined in South Indian patient

137 atment was associated with increased risk of cardiovascular outcomes except for myocardial infarction

138 b as part of the Program to Reduce LDL-C and Cardiovascular Outcomes Following Inhibition of PCSK9 in

139 Moreover, it is the one cardiovascular outcome for which the risk has been shown

140 ialysis-dependent kidney failure (DDKF), and cardiovascular outcomes) for a total of 1131 participant

141 Long-term trends in excess risk of death and cardiovascular outcomes have not been extensively studie

142 nferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88

143 dog ownership was inversely associated with cardiovascular outcomes (HR composite CVD 0.92, 95% CI,

144 presence and extent of LGE relate to overall cardiovascular outcome in cardiomyopathies.

145 ) concentrations are associated with adverse cardiovascular outcome in primary prevention populations

146 marker of oxidative capacity, with incident cardiovascular outcomes in 10,006 participants in the At

147 We assessed the relation between LGE and cardiovascular outcomes in 1293 HCM patients referred fo

148 ings were extended by examining genotype and cardiovascular outcomes in 2 independent aspirin-treated

149 , but few studies have assessed its value on cardiovascular outcomes in a broad, worldwide population

150 lationship between genotype status and major cardiovascular outcomes in a large cohort of patients wi

151 luated associations of 1,5-AG with long-term cardiovascular outcomes in a population-based setting.

152 for prevention of early recurrent stroke and cardiovascular outcomes in acute ischemic stroke and tra

153 SNPs related to cardiovascular outcomes in adulthood at least partly inf

154 r FH in childhood on lipid concentrations or cardiovascular outcomes in adulthood, or on the long-ter

155 We aimed to assess the cardiovascular outcomes in adults carrying NR3C2 mutatio

156 leotide polymorphisms (SNPs) for subclinical cardiovascular outcomes in adults.

157 British Columbia, this study evaluated major cardiovascular outcomes in all diabetic patients who und

158 , a machine learning technique, to predict 6 cardiovascular outcomes in comparison to standard cardio

159 dependent and additive predictors of adverse cardiovascular outcomes in coronary artery disease patie

160 ty (PA) is inversely associated with adverse cardiovascular outcomes in healthy populations, but the

161 etabolite trimethylamine N-oxide (TMAO) with cardiovascular outcomes in hemodialysis patients and ass

162 ar longitudinal strain (LS) is predictive of cardiovascular outcomes in HFpEF beyond clinical and con

163 that preserving immune function may improve cardiovascular outcomes in HIV-infected persons.

164 V) adaptive servo-ventilation (ASV) improved cardiovascular outcomes in hospitalized HF patients with

165 ciate circulating DPPIV activity with poorer cardiovascular outcomes in human and experimental HF.

166 tor-based therapy was associated with poorer cardiovascular outcomes in hypertensive blacks but not i

167 ial stiffness is an independent predictor of cardiovascular outcomes in hypertensive patients includi

168 ntially modifiable risk factor for death and cardiovascular outcomes in incident hemodialysis patient

169 retinal vessel calibers are associated with cardiovascular outcomes in long-term follow-up and provi

170 efficacy analyses have demonstrated similar cardiovascular outcomes in patients with AF and CHF rand

171 Whether parathyroidectomy improves cardiovascular outcomes in patients with asymptomatic pr

172 ociation between achieved blood pressure and cardiovascular outcomes in patients with coronary artery

173 the alpha-glucosidase inhibitor acarbose on cardiovascular outcomes in patients with coronary heart

174 ME) study was the first trial that evaluated cardiovascular outcomes in patients with diabetes with t

175 herapeutic techniques that improve long-term cardiovascular outcomes in patients with ESRD.

176 pharmacological heart rate lowering reduces cardiovascular outcomes in patients with heart failure,

177 y cardiac MR (CMR) is a predictor of adverse cardiovascular outcomes in patients with nonischemic car

178 e of dalcetrapib benefits on atherosclerotic cardiovascular outcomes in patients with the AA genotype

179 glucagon-like peptide 1-receptor agonist, on cardiovascular outcomes in patients with type 2 diabetes

180 rtant risk factor for graft loss and adverse cardiovascular outcomes in pediatric kidney transplantat

181 Cardiovascular outcomes in persons who were normotensive

182 an successfully increase optimism or improve cardiovascular outcomes in post-ACS patients is not yet

183 ne clinical practice could be used to detect cardiovascular outcomes in pragmatic clinical trials or

184 of renal artery stent placement, the CORAL (Cardiovascular Outcomes in Renal Atherosclerotic Lesions

185 ab is under investigation for its effects on cardiovascular outcomes in statin-treated, high-risk pat

186 hether TM6SF2 E167K affects liver damage and cardiovascular outcomes in subjects at risk of NASH.

187 d not significantly reduce long-term adverse cardiovascular outcomes in the intention-to-treat popula

188 e modeled the prevalence of risk factors and cardiovascular outcomes in the period before and after A

189 portional hazard models were used to compare cardiovascular outcomes in these 2 groups.

190 hat reduce skin sodium content might improve cardiovascular outcomes in these patients.

191 sociated with residual risk of mortality and cardiovascular outcomes in those with T1DM compared with

192 Metformin improves cardiovascular outcomes in type 2 diabetes, but its exac

193 udinal strain (GLS) is prognostic of adverse cardiovascular outcomes in various patient populations,

194 ically affect AF-related quality of life and cardiovascular outcomes in women.

195 r nasal symptoms, oxymetazoline response and cardiovascular outcomes, in turn suggesting alpha-1 rece

196 The cardiovascular outcomes included no significant CAD ( n

197 Occurrence of cardiovascular outcomes including primary composite outc

198 to determine the association between PP and cardiovascular outcomes, including cardiovascular death,

199 n 70 mm Hg were each associated with adverse cardiovascular outcomes, including mortality, supporting

200 Long-term cardiovascular outcomes, including recurrent SCAD, are i

201 whether PP is associated with major adverse cardiovascular outcomes, independently of mean arterial

202 Cardiovascular outcomes investigated were cardiovascular

203 BNP had similar predictive value for adverse cardiovascular outcomes, irrespective of AF status.

204 he global obesity epidemic and its impact on cardiovascular outcomes is a topic of ongoing debate and

205 ate (eGFR) and albuminuria for prediction of cardiovascular outcomes is controversial.

206 rome (ACS); whether they are associated with cardiovascular outcomes is unknown.

207 to-visit variability in LDL-C levels affects cardiovascular outcomes is unknown.

208 inflammatory markers; however, its effect on cardiovascular outcomes is unknown.

209 ciation between calcification morphology and cardiovascular outcomes, it is important to understand t

210 t BP lowering can significantly reduce major cardiovascular outcomes largely independent of the agent

211 lacebo, modestly reduced the risk of adverse cardiovascular outcomes, many of which were revasculariz

212 Future studies using specific cardiovascular outcomes may elucidate how alcohol affect

213 ntial benefits of statins between cancer and cardiovascular outcomes may provide a unique opportunity

214 or IL-17A in KC-Tie2 psoriasis mice improves cardiovascular outcomes, mice were treated systemically

215 ollow-up of 3.3 years, the primary composite cardiovascular outcome occurred in 112 intensive group a

216 sma aldosterone and renin levels, no adverse cardiovascular outcome occurred in pseudohypoaldosteroni

217 -converting enzyme inhibitors (ACE-i) on the cardiovascular outcome of renal transplant recipients (R

218 ACE-i was associated with better general and cardiovascular outcome of RTRs without detrimental effec

219 wever, large-scale studies of the effects on cardiovascular outcomes of adding DPP-4 inhibitors versu

220 and screened for eligibility, four trials of cardiovascular outcomes of GLP-1 receptor agonists were

221 but unproven intervention for improving the cardiovascular outcomes of solid organ transplant recipi

222 he individual drugs had different effects on cardiovascular outcomes or death (all I(2)<43%).

223 continue into adulthood and lead to adverse cardiovascular outcomes or other obesity-related morbidi

224 only intermediate physiologic measures, soft cardiovascular outcomes, or crude risk estimates.

225 k discrimination for chronic kidney disease, cardiovascular outcomes, or mortality outcomes.

226 major cardiovascular risk factors, impact on cardiovascular outcomes, outcomes research that is curre

227 Baseline measurements were used to predict cardiovascular outcomes over 12 years of follow-up.

228 sociated with increased incidence of serious cardiovascular outcomes, particularly incident stroke.

229 The true incidence of cardiovascular outcomes post-liver transplant remains un

230 erol concentration at 4 weeks and subsequent cardiovascular outcomes (primary endpoint was the compos

231 e and vilanterol did not affect mortality or cardiovascular outcomes, reduced exacerbations, and was

232 redisposing and precipitating conditions and cardiovascular outcomes remains poorly described.

233 cal link between central obesity and adverse cardiovascular outcomes remains poorly understood.

234 short-term changes in traditional lipids on cardiovascular outcomes remains to be determined.

235 betes, the impact of sulfonylurea therapy on cardiovascular outcomes remains uncertain.

236 The Centers for Cardiovascular Outcomes Research (CCORs) held a meeting

237 ogram represents a significant investment in cardiovascular outcomes research by the National Heart,

238 re extracted from the National Institute for Cardiovascular Outcomes Research clinical registry.

239 The National Institute for Cardiovascular Outcomes Research database was used to id

240 esearch (CCORs) held a meeting to review how cardiovascular outcomes research had evolved in the deca

241 itutes of Health established the Centers for Cardiovascular Outcomes Research program in 2010.

242 The Centers for Cardiovascular Outcomes Research program represents a si

243 ascular events in the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition i

244 Most notably, the FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition i

245 The recent Further Cardiovascular Outcomes Research with PCSK9 Inhibition i

246 his secondary ad hoc analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition i

247 emic climate, and a vision for the future of cardiovascular outcomes research.

248 dentify priorities and barriers to important cardiovascular outcomes research; and (3) define future

249 Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results-A Long Term Evaluation [L

250 Cox models for the primary composite cardiovascular outcome revealed a number needed to treat

251 1% [95% CI, -1.19 to -0.43%]), and composite cardiovascular outcomes (RR, 0.70 [95% CI, 0.63 to 0.78]

252 cts on Quality of Life scores, AF treatment, cardiovascular outcomes, stroke or non-central nervous s

253 ective in preclinical studies; however, some cardiovascular outcome studies revealed increased hospit

254 iabetes had roughly 40% greater reduction in cardiovascular outcomes than controls, and patients with

255 te setting resulted in a risk of a composite cardiovascular outcome that was lower than the risk amon

256 health behaviors, biological processes, and cardiovascular outcomes, the relationship between optimi

257 doses of evolocumab being studied in a large cardiovascular outcomes trial suppress PCSK9 levels and

258 double-blind, treat-to-target, event-driven cardiovascular outcomes trial.

259 ic medications, as evidenced by results from cardiovascular outcome trials (CVOTs) and large observat

260 Two cardiovascular outcome trials - Atherothrombosis Interve

261 lar safety across all GLP-1 receptor agonist cardiovascular outcome trials and suggest that drugs in

262 In contrast, cardiovascular outcome trials examining the safety of th

263 abetic drugs greatly increased the number of cardiovascular outcome trials in diabetes, but most tria

264 The results of cardiovascular outcome trials in human subjects with typ

265 imary concern is the high cost of conducting cardiovascular outcome trials in the current regulatory

266 es paper, we summarise randomised controlled cardiovascular outcome trials in type 2 diabetes, provid

267 these medications, highlighting recent large cardiovascular outcome trials investigating these therap

268 ailure should be systematically evaluated in cardiovascular outcome trials of all new glucose-lowerin

269 Cardiovascular outcome trials of antihyperglycaemic drug

270 Results from ongoing cardiovascular outcome trials of PCSK9 inhibitors will p

271 Findings from cardiovascular outcome trials showed cardiovascular safe

272 e a detailed overview and summary of ongoing cardiovascular outcome trials with SGLT2 inhibitors.

273 Few cardiovascular outcomes trials have been conducted for o

274 espectively, have published final results of cardiovascular outcomes trials in patients with clinical

275 major bleeding), and implications for future cardiovascular outcomes trials.

276 that interfere with IL-1 action can improve cardiovascular outcomes, ushering in a new era of anti-i

277 y, and analyzed the association of TMAO with cardiovascular outcomes using Cox models adjusted for po

278 nted either benefit or equivalence regarding cardiovascular outcomes versus the comparator agents in

279 te of the 1-year event rate of the composite cardiovascular outcome was 6.2% (95% confidence interval

280 The primary cardiovascular outcome was a composite of cardiovascular

281 ity therapy increase the risk of longer term cardiovascular outcomes?" We included: 1) human studies;

282 Mortality and major adverse cardiovascular outcomes were analyzed by age, sex, and C

283 Cardiovascular outcomes were assessed in 1,819 controls

284 Main cardiovascular outcomes were CVD [including ischemic hea

285 Definitions of cardiovascular outcomes were highly inconsistent.

286 Six different cardiovascular outcomes were investigated, including all

287 Cardiovascular outcomes were myocardial infarction, stro

288 Academic Research Consortium (BARC) GIB and cardiovascular outcomes were recorded within 1 year of f

289 Ezetimibe improved cardiovascular outcomes when added to statin therapy in

290 onflicting results for the effect of PPIs on cardiovascular outcomes when coadministered with DAPT.

291 The EXAMINE trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard

292 ), alogliptin (EXAMINE trial [Examination of Cardiovascular Outcomes With Alogliptin Versus Standard

293 We assessed cardiovascular outcomes with alogliptin, a new inhibitor

294 scular (CV) outcomes in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS).

295 isease at entry into TECOS (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).

296 ]), and sitagliptin (TECOS [Trial Evaluating Cardiovascular Outcomes With Sitagliptin]) found that th

297 aphic), underlying etiology, management, and cardiovascular outcomes with this condition, thus provid

298 al measure was independently associated with cardiovascular outcomes, with larger adjusted hazard rat

299 a drug providing such beneficial effects on cardiovascular outcomes, would have also the same impact

300 been associated with worsened metabolic and cardiovascular outcomes; yet, the mechanisms explaining